Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of catumaxomab by determination of the
rate of macroscopic complete remissions of peritoneal carcinomatosis after treatment with one
cycle (four doses) of catumaxomab followed by six cycles of routine neoadjuvant chemotherapy.